Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)

Inclusion Criteria: * Diagnosis of asthma of at least 6 months duration * Current use of a medium or high daily dose of an inhaled corticosteroid (ICS) (alone or in combination with a long-acting beta agonist \[LABA\]) for at least 6 weeks prior to Screening AND must be on a stable asthma regimen (daily dose unchanged) for at least 2 weeks prior to Screening * Agrees to change asthma therapy (if changing asthma therapy poses no inherent risk) * If female of reproductive potential, agrees to remain abstinent or use 2 acceptable methods of birth control during study participation. Acceptable methods of birth control are: intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, vasectomy, hormonal contraceptive Exclusion Criteria: * Treatment in the emergency room (for a severe asthma exacerbation), or admitted to the hospital for management of airway obstruction within previous 3 months * Any prior ventilator support for respiratory failure secondary to asthma, * Upper or lower respiratory tract infection (viral or bacterial) within previous 2 weeks * History of a medical condition that, in the investigator's opinion, may interfere with study participation, * History of smoking within previous year or a cumulative smoking history of more than 10 pack-years * Known allergy to or intolerance of ICSs, LABAs, or any of the ingredients included in the study medications * History of use of illicit drugs * Inability to correctly use an oral MDI * Pregnant, breastfeeding or plans to become pregnant during study